Contrast Media

Contrast media, also called contrast agents, are used to enhance the blood and perfusion in tissues. This includes iodine based contrast for on computed tomography (CT), gadolinium based agents for MRI and lipid bubble contrast agents used in ultrasound.

FDA-approved in May 2023, POSLUMA is commercially available through 36 radiopharmacies across the United States

News | Prostate Cancer

Blue Earth Diagnostics Announces Addition of POSLUMA (Flotufolastat F 18) Injection to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer

July 28, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

July 28, 2023

Scientists have found a new use for copper in magnetic resonance imaging (MRI) contrast agent design, that could help to create better images which help doctors diagnose patients’ conditions more easily and safely.

News | Magnetic Resonance Imaging (MRI)

Copper Could Help Create Clearer MRI Images and Improved Diagnosis

July 27, 2023 — Scientists have found a new use for copper in magnetic resonance imaging (MRI) contrast agent design ...

July 27, 2023

News | Contrast Media

Bracco Imaging Announces Publication of Data Reinforcing Efficacy, Safety of Gadopiclenol in Contrast-Enhanced MRI of Certain Body Regions

July 25, 2023 — Bracco Imaging has issued a statement on new results published in the journal Radiology which found that ...

July 25, 2023

Sponsored Content

Blog | Contrast Media Injectors

BLOG: Smart Injector Technology Delivers Effective and Efficient Patient Care

Technology advancements are changing consumers’ expectations, driving industries to adapt and evolve, and the healthcare ...

April 29, 2021

Comprehensive clinical development program called QUANTI includes two Phase III studies in adults and one pediatric study investigating gadoquatrane for use in MRI across all body regions and across ages from birth to adulthood

News | Contrast Media

Bayer initiates Phase III Studies with Investigational Contrast Agent Gadoquatrane

July 7, 2023 — Bayer, a global leader in radiology, has initiated the Phase III clinical development program called ...

July 06, 2023

Preferential use of pulmonary MR angiography (MRA) for diagnosing pulmonary embolus (PE) in the general population helped conserve iodinated contrast media during the 2022 shortage

News | Contrast Media

Switch to MR Angiography for PE Mitigated Impact of Recent Contrast Shortage

July 3, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR) ...

July 03, 2023

Contrast-enhanced mammography (CEM) is an emerging modality combining digital mammography with the administration of a contrast agent

News | Contrast Media

FDA approves Bayer’s Ultravist (iopromide) Injection for Contrast-enhanced Mammography

June 26, 2023 — Bayer announced that Ultravist (iopromide)-300, -370, its iodine-based contrast agent, has been approved ...

June 26, 2023

Sponsored Content

Case Study | Contrast Media Injectors

Steinberg Diagnostic Medical Imaging

Steinberg Diagnostic Medical Imaging (SDMI) was founded 30 years ago and has grown to be one of the largest outpatient ...

January 21, 2021

Therapeutically equivalent and fully substitutable to Kinevac (Sincalide for Injection) formulated, filled and packaged in the United States provides health care facilities with choice and value

News | Contrast Media

Fresenius Kabi Broadens Radiology Portfolio with its First-to-Market Authorized Generic, Sincalide for Injection

June 21, 2023 — Fresenius Kabi, a leading provider of injectable medicines, announced today it has launched the ...

June 21, 2023

News | Contrast Media

MRI Contrast Agent Orviglance Hepatic Impairment Data Presented by Ascelia Pharma at ESGAR 2023

June 20, 2023 — Ascelia Pharma presented data from its Orviglance Hepatic Impairment study during the European Society ...

June 20, 2023

VUEWAY (gadopiclenol) solution for injection and VUEWAY (gadopiclenol) Pharmacy Bulk Package are available for use in the U.S. following the market launch in February 20231

News | Contrast Media

American College of Radiology Classifies VUEWAY as a Group II Agent Relative to NSF

May 16, 2023 — Bracco Imaging, an innovative world leader delivering end-to-end products and solutions through a ...

May 16, 2023

Sponsored Content

When new installations are ordered, the DAS team at Bracco matches a specialist with the installation based on specialty, learning style and industry awareness. This approach was helpful at Beaufort Memorial Hospital in Beaufort, S.C., which just recently transitioned to the Bracco EmpowerCTA+ Injector System.

Blog | Contrast Media

BLOG: Training and Vendor Support Key to Successful Device Upgrade

Transitioning to a new device vendor can provide improvements to outdated technology and workflow. It also requires a ...

October 20, 2020

Elucirem, a novel new macrocyclic GBCA for use in contrast-enhanced magnetic resonance imaging (MRI), has the highest relaxivity compared to other non-specific GBCAs (gadolinium-based contrast agents)

News | Contrast Media

Guerbet Announces ACR Committee on Drugs and Contrast Media Classifies Elucirem (Gadopiclenol) Injection a Group II Agent

May 15, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced that ...

May 15, 2023

In the past year, the radiology community has been a first-hand, hands-on witness to myriad unexpected challenges and unprecedented partnerships emerging on the scene of the contrast media market

Feature | Contrast Media | By Christine Book

A Look Inside the Contrast Media Market

In the past year, the radiology community has been a first-hand, hands-on witness to myriad unexpected challenges and ...

May 03, 2023

At the urging of the American College of Radiology (ACR) and others, the US Food and Drug Administration will now recommend thyroid monitoring only for high-risk young children who receive intravascular iodine-containing contrast media for thyroid dysfunction

News | Pediatric Imaging

ACR-Backed FDA Action to Monitor Young At-Risk Children Who Receive Iodinated Contrast Media

April 28, 2023 — At the urging of the American College of Radiology (ACR) and others, the US Food and Drug ...

April 28, 2023

Sponsored Content

The radiology department uses Bracco’s Empower CTA injector system and has a been a Bracco customer for more than 15 years.

Blog | Contrast Media Injectors

BLOG: Reliability and Customer Service Key to Injector Uptime and CT Department

In a busy hospital imaging department, maintaining high device uptime levels is critical. If an injector malfunctions or ...

August 20, 2020

News | PET Imaging

Nuclidium and University Hospital Basel Receive NETRF Investigator Award to Initiate Phase 1 Trial with Novel Copper-based Radiotheranostic Program TraceNET in Neuroendocrine Tumors

March 23, 2023 — Nuclidium announced that the Neuroendocrine Tumors Research Foundation (NETRF) has selected the company ...

March 24, 2023

Reveal Pharmaceuticals doses first subjects in Phase 1 Clinical Trial of RVP‑001

News | Contrast Media

New Gadolinium-Free MRI Contrast Agent Advances Safer Patient Care

March 9, 2023 — Contrast agents used in MRI scans to improve the clarity of imaging for diagnostic accuracy, accumulate ...

March 09, 2023

Novel manganese-based macrocyclic Magnetic Resonance Imaging (MRI) agent could offer an alternative to gadolinium-based agents

News | Contrast Media

GE HealthCare Announces Completion of Phase I Subject Recruitment in Early Clinical Development Program for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent

March 2, 2023 — GE HealthCare announced at the European Congress of Radiology (ECR) in Vienna, Austria, the completion ...

March 02, 2023

Ascelia Pharma has announced the successful completion of patient enrollment in its pivotal phase 3 clinical study, SPARKLE, with the lead candidate drug Orviglance, the company’s novel MRI contrast agent for patients with impaired kidney function.

News | Radiation Oncology

Swedish Biotech Ascelia Pharma Meets Milestone in SPARKLE Phase 3 Study Using Novel MRI Contrast Agent

March 2, 2023 — Ascelia Pharma, a biotech company focused on improving the life of people living with rare cancer ...

March 02, 2023

Sponsored Content | Videos | Contrast Media

VIDEO: Talking Trends with Bracco: Investing in the Future of Radiology

Bracco Diagnostics and Guerbet recently announced they had formed a strategic, global collaboration for the research ...

February 27, 2023

Contrast-enhanced ultrasound (CEUS) is more accurate and reliable than MRI for examining certain liver and kidney nodules

News | Ultrasound Imaging

Enhanced Ultrasound Superior to MRI for Diagnosing Certain Liver and Kidney Tumors, According to New Studies

February 24, 2023 — Contrast-enhanced ultrasound (CEUS) is more accurate and reliable than MRI for examining certain ...

February 24, 2023

First dosage administered at the Hospital of the University of Pennsylvania following FDA approval

News | Contrast Media

Guerbet Announces Commercial Launch and First Patient Dosing of Elucirem (Gadopiclenol) Injection

February 16, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced ...

February 16, 2023

Requiring half the gadolinium dosage compared to other macrocyclic gadolinium-based contrast agents (GBCAs) in approved indications in the U.S., gadopiclenol also has the highest relaxivity compared to approved GBCAs1-7

News | Contrast Media

First Nationwide Use of Bracco's VUEWAY (gadopiclenol) Solution for Injection for MRI

February 15, 2023 — Bracco Imaging, an innovative world leader delivering end-to-end products and solutions through a ...

February 15, 2023